KEYSER D JEFFREY 4

What Happened Jeffrey D. Keyser, a director of Lantern Pharma (LTRN), acquired 48,544 common shares on May 12, 2026, at $2.06 per share for a total cash outlay of $100,001. The filing also reports a related derivative entry of 48,544 units shown as disposed at $0; a footnote indicates the reported securities were part of the issuer's offering that closed May 14, 2026 and that associated warrants are exercisable beginning November 14, 2026. This transaction is a purchase (a straightforward insider buy), which many retail investors view as a more informative sign than routine sales.

Key Details

• Transaction date: May 12, 2026
• Purchase: 48,544 shares @ $2.06 each = $100,001 total
• Derivative reported: 48,544 units disposed at $0 (see footnote about offering/warrants)
• Footnote: Securities were acquired in the issuer’s offering that closed May 14, 2026; warrants exercisable commencing Nov 14, 2026
• Filing date: May 14, 2026 (filed within the usual two‑business‑day Form 4 window)
• Shares owned after transaction: Not specified in the provided filing excerpt

Context

• The acquired warrants noted in the filing are not currently exercisable; they become exercisable on Nov 14, 2026, per the footnote.
• The purchase is a direct cash buy rather than an option exercise or a gift, so it reflects an insider adding to equity rather than converting compensation.
• The filing appears timely; no late‑filing flag was indicated in the provided information.